Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd.
Explore linked clinical trials.12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia | Functional Dyspepsia | Recruiting | Phase 4 | 2026-08-10 | NCT07686679 | |
| Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature | Bone Diseases, Developmental, Bone Diseases, Endocrine, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dwarfism, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Sex Chromosome Disorders, Turner syndrome, Urogenital Abnormalities, Urogenital Diseases, bone disorder, brain disorder, cardiovascular disorder, central nervous system disorder, chromosomal disorder, congenital heart disease, disorder of sexual differentiation, endocrine system disorder, gonadal disorder, gonadal dysgenesis, heart disorder, hereditary disease, hypopituitarism, hypothalamic disorder, musculoskeletal system disorder, nervous system disorder, pituitary dwarfism, pituitary gland disorder, sex chromosome disorder of sex development | Recruiting | Not stated | 2026-07-21 | NCT04798690 | |
| A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal cancer, neoplasm, stomach disorder | Recruiting | Phase 1 | 2026-05-20 | NCT07481357 | |
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-12-31 | NCT05845489 | |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Not yet recruiting | Phase 2 | 2025-11-20 | NCT07239440 | |
| Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2025-11-19 | NCT06290349 | |
| Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Not yet recruiting | Phase 4 | 2025-11-17 | NCT07229534 | |
| The Effect of Two Prokinetics in Patients With Functional Dyspepsia | Functional Dyspepsia | Active, not recruiting | Not applicable | 2025-08-05 | NCT07096921 | |
| Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects | Healthy | Not yet recruiting | Phase 1 | 2025-06-06 | NCT06993181 | |
| To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects | Healthy | Not yet recruiting | Phase 1 | 2025-05-28 | NCT06993168 | |
| A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Not applicable | 2025-04-24 | NCT06627322 | |
| Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-02-12 | NCT06293651 |